IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas.
Sign Up to like & getrecommendations! Published in 2022 at "American journal of clinical pathology"
DOI: 10.1093/ajcp/aqac044
Abstract: OBJECTIVES Interferon regulatory factor 8 (IRF8) is a new biomarker shown to be positive in monocytic leukemias as well as in B cells. As a transcription factor, it plays a critical role in pre-B-cell differentiation… read more here.
Keywords: cd30 positive; cell; cell lymphomas; large cell ... See more keywords
Use of brentuximab vedotin as salvage therapy pre‐allogeneic stem cell transplantation in relapsed/refractory CD30 positive lympho‐proliferative disorders: a single centre experience
Sign Up to like & getrecommendations! Published in 2017 at "Internal Medicine Journal"
DOI: 10.1111/imj.13415
Abstract: The role of brentuximab peri‐allogeneic transplantation in patients with relapsed and/or refractory CD30 positive lymphomas remains poorly defined. read more here.
Keywords: relapsed refractory; transplantation; cd30 positive; brentuximab ... See more keywords
Role of Stem Cell Transplant in CD30-positive PTCL following Frontline Brentuximab Vedotin+CHP or CHOP in ECHELON-2.
Sign Up to like & getrecommendations! Published in 2022 at "Blood advances"
DOI: 10.1182/bloodadvances.2020003971
Abstract: Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of aggressive non-Hodgkin lymphomas, the majority of which have a high relapse rate following standard therapy. Despite use of consolidative stem cell transplant (SCT) following frontline therapy,… read more here.
Keywords: positive ptcl; cd30 positive; chp; pfs ... See more keywords
A phase II open-label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30-positive peripheral T-cell lymphoma or transformed mycosis fungoides: The REDIRECT study design and rationale.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.tps3148
Abstract: TPS3148Background: AFM13 is a tetravalent, bispecific (anti-CD30/anti-CD16A) recombinant antibody being developed for the treatment of CD30-positive T-cell malignancies and Hodgkin lymphoma. AFM13 ... read more here.
Keywords: cd30; afm13; study; phase open ... See more keywords
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
Sign Up to like & getrecommendations! Published in 2020 at "Haematologica"
DOI: 10.3324/haematol.2019.238675
Abstract: We conducted a phase I/II multicenter trial using six cycles of brentuximab vedotin (BV) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for treatment of patients with CD30-positive B-cell lymphomas. Thirty-one patients were evaluable… read more here.
Keywords: treatment; cd30 positive; combination rituximab; brentuximab vedotin ... See more keywords
Deep Sequencing of Immunoglobulin Genes Identifies a Very Low Percentage of Monoclonal B Cells in Primary Cutaneous Marginal Zone Lymphomas with CD30-Positive Hodgkin/Reed–Sternberg-like Cells
Sign Up to like & getrecommendations! Published in 2022 at "Diagnostics"
DOI: 10.3390/diagnostics12020290
Abstract: The spectrum of cutaneous CD30-positive lymphoproliferative disorders encompasses both inflammatory and neoplastic conditions. CD30+ Hodgkin and Reed–Sternberg-like cells have been occasionally reported in primary cutaneous marginal zone lymphoma, where they are thought to represent a… read more here.
Keywords: cd30 positive; primary cutaneous; cutaneous marginal; marginal zone ... See more keywords